Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Debt / NOTE 3.000% 6/0
-
Market price (% of par)
-
135.71%
-
Total 13F principal
-
$130,856,000
-
Principal change
-
-$1,696,000
-
Total reported market value
-
$177,452,000
-
Number of holders
-
13
-
Value change
-
-$5,415,784
-
Number of buys
-
7
-
Number of sells
-
5
Institutional Holders of ARRAY BIOPHARMA INC - NOTE 3.000% 6/0 as of Q2 2017
As of 30 Jun 2017,
ARRAY BIOPHARMA INC - NOTE 3.000% 6/0 was held by
13 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$130,856,000
in principal (par value) of the bond.
The largest 10 bondholders included
CITADEL ADVISORS LLC, WOLVERINE ASSET MANAGEMENT LLC, Redmile Group, LLC, CSS LLC/IL, TENOR CAPITAL MANAGEMENT Co., L.P., LINDEN ADVISORS LP, LAZARD ASSET MANAGEMENT LLC, BAKER BROS. ADVISORS LP, GABELLI FUNDS LLC, and JPMORGAN CHASE & CO.
This page lists
13
institutional bondholders reporting positions
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.